Key terms
About PHVS
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PHVS news
Yesterday
1:29am ET
Pharvaris’s Promising Drug Candidate Deucrictibant Bolsters Buy Rating
May 09
8:35am ET
Pharvaris price target lowered to $31 from $35 at Wedbush
May 09
7:59am ET
Wedbush Keeps Their Buy Rating on Pharvaris (PHVS)
May 09
1:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Steris (STE), Pharvaris (PHVS)
May 08
6:06pm ET
Pharvaris reports Q1 EPS (EUR 0.52) vs. (EUR 0.67) last year
May 08
4:59pm ET
Pharvaris Advances HAE Treatment in Solid Q1 2024
Apr 14
9:25pm ET
Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment
Apr 12
4:22pm ET
Pharvaris files automatic mixed securities shelf
Apr 12
2:00am ET
Pharvaris N.V.’s High-Stakes Gamble: Navigating Clinical Trials and Regulatory Hurdles for Market Success
Apr 12
1:39am ET
Buy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financials
Apr 11
6:12am ET
Pharvaris price target raised to $50 from $49 at JMP Securities
Apr 10
4:15pm ET
Pharvaris reports Q4 EPS (EUR 0.74) vs. (EUR 1.16) last year
Apr 10
4:12pm ET
Pharvaris appoints David Nassif as CFO
Mar 21
2:19am ET
Optimistic Buy Rating for Pharvaris on Advancement in Phase 3 HAE Treatment Trial
Mar 19
8:50am ET
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)
Mar 18
10:55am ET
Pharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial Prospects
Mar 18
6:51am ET
Pharvaris initiates RAPIDe-3, the Phase 3 clinical trial
Mar 13
7:40am ET
Analysts Are Bullish on Top Healthcare Stocks: biote (BTMD), Incyte (INCY)
Mar 06
4:42pm ET
Pharvaris files to sell 5.55M ordinary shares for holders
Feb 26
12:25am ET
Pharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE Treatment
Feb 22
7:14am ET
Pharvaris’ deucrictibant shows positive results in HAE attacks
Feb 13
4:35pm ET
Pharvaris’s Deucrictibant: A Buy Rating on the Horizon of HAE Treatment Innovation
No recent press releases are available for PHVS
PHVS Financials
Key terms
Ad Feedback
PHVS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PHVS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
